- Home
- STHO vs ADCT Comparison
STHO vs ADCT Comparison
Compare STHO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STHO | ADCT |
|---|---|---|
| Founded | 2022 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.0M | 136.1M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | STHO | ADCT |
|---|---|---|
| Price | $7.81 | $1.72 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 38.8K | ★ 1.5M |
| Earning Date | 11-17-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 24.73 | ★ 30.86 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $110,143,000.00 | $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.32 |
| P/E Ratio | $3.05 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $7.01 | $0.78 |
| 52 Week High | $9.94 | $4.98 |
Technical Indicators
Market Signals| Indicator | STHO | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.37 | 54.68 |
| Support Level | $7.76 | $1.01 |
| Resistance Level | $8.20 | $1.87 |
| Average True Range (ATR) | 0.25 | 0.13 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 50.59 | 51.61 |
Price Performance
Historical ComparisonAbout STHO Star Holdings Shares of Beneficial Interest
Star Holdings engages in non-ground lease-related businesses, including real estate finance, operating properties, and land and development. Its portfolio is comprised of its interests in Asbury and Magnolia Green residential development projects, a portfolio of commercial real estate properties, and loans that are being marketed for sale. The Company operates its business through one reportable and operating segment that focuses on realizing value for shareholders by generating cash flows through active asset management and sales of its existing loans, operating properties, and land and development properties.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).